Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Last Patient enrolled recovers in 10 days, great news

<< Previous

Bullboard Posts

Next >>

Comment by talisman47on Dec 24, 2020 10:25pm

157 Views

Post# 32182185

RE:Last Patient enrolled recovers in 10 days, great news

Where did you see that the patient was releaswed from hospital ?? I read it that the last patient was on medication for 15 days and then there was a two week follow up to analyse data. It would be fantastic if they were released 4-5 days faster than average.

Please advise. Thanks

<< Previous

Bullboard Posts

Next >>

Sony’s Alpha 1 II: A new professional photography standard?